Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome

被引:291
作者
Manuelian, T
Hellwage, J
Meri, S
Caprioli, J
Noris, M
Heinen, S
Jozsi, M
Neumann, HPH
Remuzzi, G
Zipfel, PF
机构
[1] Hans Knoell Inst Nat Prod Res, Dept Infect Biol, D-07745 Jena, Germany
[2] Haartman Inst, Dept Bacteriol & Immunol, Helsinki, Finland
[3] Mario Negri Inst Pharmacol Res, I-24100 Bergamo, Italy
[4] Univ Freiburg, Dept Nephrol, Freiburg, Germany
关键词
D O I
10.1172/JCI200316651
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Hemolytic uremic syndrome (HUS) is a disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Recent studies have identified a factor H-associated form of HUS, caused by gene mutations that cluster in the C-terminal region of the complement regulator factor H. Here we report how three mutations (E1172Stop, R1210C, and R1215G; each of the latter two identified in three independent cases from different, unrelated families) affect protein function. All three mutations cause reduced binding to the central complement component C3b/C3d to heparin, as well as to endothelial cells. These defective features of the mutant factor H proteins explain progression of endothelial cell and microvascular damage in factor H-associated genetic HUS and indicate a protective role of factor H for tissue integrity during thrombus formation.
引用
收藏
页码:1181 / 1190
页数:10
相关论文
共 40 条
  • [1] Human factor H deficiency - Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism
    Ault, BH
    Schmidt, BZ
    Fowler, NL
    Kashtan, CE
    Ahmed, AE
    Vogt, BA
    Colten, HR
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (40) : 25168 - 25175
  • [2] Blackmore TK, 1998, J IMMUNOL, V160, P3342
  • [3] Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome
    Buddles, MRH
    Donne, RL
    Richards, A
    Goodship, J
    Goodship, THJ
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 66 (05) : 1721 - 1722
  • [4] Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297
  • [5] REGULATION OF THE ACTIVITY OF PLATELET-BOUND C-3 CONVERTASE OF THE ALTERNATIVE PATHWAY OF COMPLEMENT BY PLATELET FACTOR-H
    DEVINE, DV
    ROSSE, WF
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (16) : 5873 - 5877
  • [6] DiScipio RG, 1998, J IMMUNOL, V160, P4057
  • [7] Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack
    Fedarko, NS
    Fohr, B
    Robey, PG
    Young, MF
    Fisher, LW
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (22) : 16666 - 16672
  • [8] GORDON DL, 1995, J IMMUNOL, V155, P348
  • [9] Hindmarsh EJ, 1998, J IMMUNOL, V160, P6128
  • [10] Jokiranta TS, 2000, J BIOL CHEM, V275, P27657